Nobuko Hijiya, MD, Columbia University Irving Medical Center, New York City, NY, discusses the rationale and aims of the ongoing Phase Ib/II ASC4KIDS study (NCT04925479), which is investigating dosage and safety of asciminib in pediatric patients with chronic myeloid leukemia (CML) in chronic phase. Children with CML often experience unique side effects which are especially seen during treatment with existing tyrosine kinase inhibitors (TKIs). Asciminb is a new class of drug, specifically targeting the ABL myristoyl pocket (STAMP), which has encouraging safety data from studies in adult patients with CML. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
